Ghatnekar, Ola, Frida Hjalte, and Matthew Taylor. “Cost-Effectiveness of Dasatinib Versus High-Dose Imatinib in Patients With Chronic Myeloid Leukemia (CML), Resistant to Standard Dose Imatinib – a Swedish Model Application”. Acta Oncologica 49, no. 6 (August 1, 2010): 851–858. Accessed April 26, 2026. https://medicaljournalssweden.se/actaoncologica/article/view/32708.